8-K - Northwest Biotherapeutics, Inc. | StockGist

Current Report Details

Event Type

Material Agreement

Financing

Disclosure

Mandatory

Variant

8-K

Items Reported

1.01

. Entry into a Material Definitive Agreement. Loan Entered Into On October 27, 2025, Northwest Biotherapeutics, Inc. (the “Company”) entered into a Commercial L

Material Agreement

$5.5M

2.03

. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information included in Item 1.01 of th

Financing

Exhibits (1)

8-K

FORM 8-K